How much is Johnson & Johnson committing to resolve the ovarian talc claims?

The Company has committed $5.5 billion in total under the proposed agreement, paid on a per-claim basis across the remaining ovarian talc claims.

When will the payments be made?

The first payment will be no more than $3 billion and is due in 2027. No additional payments are due before 2028, which spreads the remaining cash outflows over subsequent years.

What conditions must be met for the settlement to take effect?

The agreement is conditioned on, among other things, the participation of lead plaintiff firms in all pending ovarian talc litigation in state and federal court, representing at least 95% of the remaining claims. If the threshold is not met, the resolution may not proceed as proposed.

Why did the company reach this agreement now?

The company points to the July 22, 2026 MDL court order requiring plaintiffs to show why claims should not be dismissed for failure to prove specific causation, after plaintiffs withdrew their causation experts in two bellwether cases. Management says it remains confident it would have prevailed with further litigation but views this as an efficient way to end the matter.

Does the filing disclose the financial impact on earnings?

No. The 8-K and press release do not disclose an accounting charge, reserve, or expected effect on earnings or cash flow beyond the $5.5 billion commitment and payment timing. Investors should look to future periodic filings for the accounting treatment.

JNJ 8-K: Regulation FD — Jul 28, 2026

01—Abstract

Summary

Summary of the 8-K filed July 28, 2026. Cited figures are marked; the original filing is the authoritative source.

Johnson & Johnson disclosed in an 8-K filed July 28, 2026 (press release dated July 27, 2026) that it has reached a proposed agreement to comprehensively resolve the ovarian talc litigation with the plaintiff firms leading the federal Multi-District Litigation (MDL) and related state court proceedings.

The deal is conditioned on, among other things, participation by plaintiff firms representing at least 95% of the remaining claims, and calls for per-claim payments with a total Company commitment of $5.5 billion^a. The first payment is capped at no more than $3 billion and is due in 2027, with no additional payments due before 2028. The company frames the agreement as an efficient end to litigation covering roughly 76,000 remaining ovarian talc claims.

The announcement follows a July 22, 2026 MDL court ruling that ordered plaintiffs to show cause why remaining claims should not be dismissed for inability to prove specific causation, after plaintiffs withdrew their specific causation experts in two bellwether cases. Management attributes the settlement to this favorable development and says it remains confident it would have prevailed at trial, given its record in ovarian cases tried to date. The company also notes it previously settled about 95%^b of filed mesothelioma lawsuits, all state consumer protection claims, and all talc-supplier disputes.

For investors, the key points are the size and timing of the commitment: $5.5 billion in total, with a first payment of up to $3 billion^c in 2027, which spreads cash outflows over multiple years. The filing does not disclose an accounting charge, reserve amount, or the effect on earnings, and the 95% participation threshold means completion is not assured. The release also includes standard forward-looking statement cautions, and the company states it cannot predict the timing or ultimate financial impact of the matter.

02—Key points

Key Highlights

Proposed comprehensive resolution of ovarian talc litigation covering approximately 76,000 remaining claims in federal MDL and state court proceedings.
Total Company commitment of $5.5 billion, structured as per-claim payments.
First payment capped at no more than $3 billion, due in 2027; no additional payments before 2028.
Agreement is conditioned on participation by plaintiff firms representing at least 95% of remaining claims, so completion is not assured.
Settlement follows a July 22, 2026 MDL court order to show cause on specific causation, after plaintiffs withdrew causation experts in two bellwether cases.
Filing does not quantify an accounting charge or reserve; the financial statement impact remains to be determined.
Company reiterates that talc products are safe and that claims lack scientific merit, and says the deal resolves a long-running matter.

03—Questions

Frequently Asked Questions

How much is Johnson & Johnson committing to resolve the ovarian talc claims?
The Company has committed $5.5 billion in total under the proposed agreement, paid on a per-claim basis across the remaining ovarian talc claims.
When will the payments be made?
The first payment will be no more than $3 billion and is due in 2027. No additional payments are due before 2028, which spreads the remaining cash outflows over subsequent years.
What conditions must be met for the settlement to take effect?
The agreement is conditioned on, among other things, the participation of lead plaintiff firms in all pending ovarian talc litigation in state and federal court, representing at least 95% of the remaining claims. If the threshold is not met, the resolution may not proceed as proposed.
Why did the company reach this agreement now?
The company points to the July 22, 2026 MDL court order requiring plaintiffs to show why claims should not be dismissed for failure to prove specific causation, after plaintiffs withdrew their causation experts in two bellwether cases. Management says it remains confident it would have prevailed with further litigation but views this as an efficient way to end the matter.
Does the filing disclose the financial impact on earnings?
No. The 8-K and press release do not disclose an accounting charge, reserve, or expected effect on earnings or cash flow beyond the $5.5 billion commitment and payment timing. Investors should look to future periodic filings for the accounting treatment.

04—Continue

← View all 8-K filings